Background and aims Patients with peripheral artery disease (PAD) are at a very high risk of
cardiovascular events and strongly benefit from lowering LDL cholesterol (LDL-C); updated …

Introduction Statins remain the first-line treatment for secondary prevention of cardiovascular
(CV) events, with lowering of low-density lipoprotein cholesterol (LDL-C) being their …

Background: Statin therapy is recommended for patients with peripheral artery disease
(PAD). However, PAD patients with polyvascular (PV) extent remain threatened by an …

Aims: The HEYMANS study observed patients receiving evolocumab as part of routine
clinical hyperlipidemia management. It was designed to capture data on clinical parameters …

The PAD population is at increased risk of major adverse cardiovascular events (MACE) and
major adverse limb events (MALE). Risk factor modification, symptom control, antithrombotic …

Background: Statin intolerance (SI) is often documented in patients' charts but rarely
confirmed by objective methods. Objective: We aimed to identify the rate of true SI in a large …

3. Conclusions This joint statement from the EAS and the ESVM provides clinical guidance
for the management of dyslipidaemia and thrombotic factors in patients with PAD …

Introduction: Peripheral arterial disease (PAD) treatment guidelines recommend the use of
statins and antiplatelets in all PAD patients to reduce adverse cardiovascular and limb …

Background: The impact of diabetes on incident cardiovascular disease in relation to the
extent of atherosclerotic disease remains unclear. We aimed to investigate major adverse …

Актуальность. Атеросклеротическое заболевание артерий нижних конечностей
(АЗАНК), или атеросклероз периферических сосудов, поражает как мужчин, так и …